| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1074-5521(99)80088-X |
| P698 | PubMed publication ID | 10421767 |
| P2093 | author name string | P Cohen | |
| M Goedert | |||
| F T Boyle | |||
| N Hewitt | |||
| C A Hall-Jackson | |||
| P A Eyers | |||
| H Plant | |||
| P Hedge | |||
| P2860 | cites work | The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling | Q24337017 |
| A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction | Q24338592 | ||
| Nuclear localization and regulation of erk- and rsk-encoded protein kinases | Q24606980 | ||
| Signal transduction by receptors with tyrosine kinase activity | Q27860624 | ||
| Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation | Q28131755 | ||
| Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling | Q28268458 | ||
| The complexity of Raf-1 regulation | Q28305850 | ||
| Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts | Q28609143 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras | Q29617087 | ||
| Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases | Q29618331 | ||
| Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane | Q29618478 | ||
| Activation of Raf as a result of recruitment to the plasma membrane | Q29618481 | ||
| The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase | Q34432656 | ||
| Protein isoprenylation and methylation at carboxyl-terminal cysteine residues | Q35671041 | ||
| Hyperexpression of mitogen-activated protein kinase in human breast cancer | Q37365431 | ||
| KSR: a novel player in the RAS pathway | Q40922759 | ||
| Insulin stimulation of gene expression mediated by p21ras activation. | Q41080652 | ||
| The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase. | Q41128592 | ||
| The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated prote | Q41437636 | ||
| Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor | Q41978360 | ||
| A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase | Q42029877 | ||
| Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution | Q42541263 | ||
| Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket | Q47982160 | ||
| [29] Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf | Q58438199 | ||
| EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor | Q72787935 | ||
| Effect of SB 203580 on the activity of c-Raf in vitro and in vivo | Q77733964 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 559-568 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | Chemistry and Biology | Q15758410 |
| P1476 | title | Paradoxical activation of Raf by a novel Raf inhibitor | |
| P478 | volume | 6 |
| Q90459957 | A Live-Cell Screen for Altered Erk Dynamics Reveals Principles of Proliferative Control |
| Q43203166 | Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. |
| Q92642778 | Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma |
| Q38233135 | Aggressive behavior and anaplasia in pleomorphic xanthoastrocytoma: a plea for a revision of the current WHO classification |
| Q40164038 | Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition |
| Q36973814 | Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy |
| Q40749465 | Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. |
| Q33808352 | Anticancer drug targets: growth factors and growth factor signaling |
| Q39362181 | Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines |
| Q42733647 | BRAF targeted therapy changes the treatment paradigm in melanoma |
| Q89622544 | Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling |
| Q43120316 | Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons |
| Q24597152 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma |
| Q54325214 | Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. |
| Q36117930 | Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development |
| Q27333987 | Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors |
| Q92573085 | Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma |
| Q38123513 | Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. |
| Q45947436 | Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. |
| Q34293560 | Development of anticancer drugs targeting the MAP kinase pathway |
| Q58806326 | Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer |
| Q40635020 | Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation |
| Q33859300 | Discovering novel chemotherapeutic drugs for the third millennium |
| Q24652600 | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity |
| Q57471980 | Drug repurposing: progress, challenges and recommendations |
| Q35163434 | Drugging the undruggable RAS: Mission possible? |
| Q43849887 | Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro |
| Q64982333 | Effect of isouronium/guanidinium substitution on the efficacy of a series of novel anti-cancer agents. |
| Q38145387 | Emerging BRAF inhibitors for melanoma. |
| Q38873500 | Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic |
| Q93049269 | Essential Oil of Mentha aquatica var. Kenting Water Mint Suppresses Two-Stage Skin Carcinogenesis Accelerated by BRAF Inhibitor Vemurafenib |
| Q34608239 | Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders |
| Q41763132 | Fluorescent cascade and direct assays for characterization of RAF signaling pathway inhibitors |
| Q44028730 | GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain |
| Q38307398 | Going for broke: targeting the human cancer pseudokinome |
| Q40138092 | Helicobacter pylori stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and -independent ERK activation |
| Q55261330 | Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift. |
| Q43470663 | How blocking Raf activates the MAPK pathway |
| Q53302291 | Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells |
| Q40623583 | IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase |
| Q40364273 | Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen |
| Q35125012 | In situ kinase profiling reveals functionally relevant properties of native kinases |
| Q54976914 | Induction of nerve growth factor by phorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway. |
| Q28577967 | Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074 |
| Q40433984 | Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs |
| Q96576802 | Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity |
| Q39847621 | Inhibitor hijacking of Akt activation |
| Q38065119 | It takes two to tango--signalling by dimeric Raf kinases |
| Q35635353 | JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis |
| Q28554490 | Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle |
| Q34527876 | Kinase drug discovery--what's next in the field? |
| Q24298749 | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF |
| Q27322966 | LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase |
| Q24532168 | Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions |
| Q38197024 | Mechanism and consequences of RAF kinase activation by small-molecule inhibitors |
| Q33557376 | Medullary thyroid carcinoma: targeted therapies and future directions |
| Q47688064 | New perspectives for targeting RAF kinase in human cancer. |
| Q56994432 | New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors |
| Q37179117 | Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors |
| Q37856375 | Occupational hazards: allosteric regulation of protein kinases through the nucleotide-binding pocket |
| Q26774625 | Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells |
| Q40738816 | PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. |
| Q24804854 | PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors |
| Q24606438 | PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells |
| Q40855036 | Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation |
| Q39873892 | Progression of RAS-mutant leukemia during RAF inhibitor treatment |
| Q37656270 | Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. |
| Q37417742 | Protein kinase inhibitors: contributions from structure to clinical compounds |
| Q29616828 | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF |
| Q43167319 | RAF modulators and methods of use. |
| Q37048053 | RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors |
| Q24316181 | Raf family kinases: old dogs have learned new tricks |
| Q36559414 | Raf kinases: oncogenesis and drug discovery |
| Q30404024 | Ras history: The saga continues |
| Q38739118 | Ras triggers acidosis-induced activation of the extracellular-signal-regulated kinase pathway in cardiac myocytes |
| Q34660771 | Ras/Raf signalling and emerging pharmacotherapeutic targets |
| Q28603650 | Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF |
| Q28603655 | Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth |
| Q44407068 | Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways |
| Q34667918 | Role of mitogen- and stress-activated kinases in ischemic injury |
| Q24645668 | Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q34406349 | Secondhand smoke exposure causes bronchial hyperreactivity via transcriptionally upregulated endothelin and 5-hydroxytryptamine 2A receptors |
| Q37004743 | Selective Raf inhibition in cancer therapy |
| Q39675037 | Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth |
| Q44355364 | Serine 338 phosphorylation is dispensable for activation of c-Raf1. |
| Q35166852 | Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. |
| Q34447484 | Signaling Mechanisms in Neuroendocrine Tumors as Targets for Therapy |
| Q41908921 | Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase |
| Q38911486 | Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation |
| Q33936548 | Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. |
| Q54119583 | Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. |
| Q28344791 | Specificity and mechanism of action of some commonly used protein kinase inhibitors |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q89462334 | Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity |
| Q28397558 | Striatal microRNA controls cocaine intake through CREB signalling |
| Q47393972 | Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets |
| Q97527711 | Targeting dementias through cancer kinases inhibition |
| Q37109225 | Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q37148789 | Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway |
| Q21629049 | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner |
| Q37290440 | The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics |
| Q47549324 | The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma |
| Q24654622 | The selectivity of protein kinase inhibitors: a further update |
| Q34275807 | The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF |
| Q64880508 | The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q38081987 | Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations |
| Q36790872 | Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells |
| Q24797025 | Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure |
| Q28276886 | Vemurafenib: the first drug approved for BRAF-mutant cancer |
| Q24600930 | ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines |
| Q40008963 | ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line |
| Q42502504 | p38 MAP kinase negatively regulates cyclin D1 expression in airway smooth muscle cells |
| Q34483284 | p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. |
Search more.